Login Register Cart 0
Generic placeholder image

Current Neurovascular Research

Editor-in-Chief

ISSN (Print): 1567-2026
ISSN (Online): 1875-5739

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Early Post-stroke Depressive Symptoms are Associated with Low Peripheral Levels of Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) and Glial Cell-derived Neurotrophic Factor (GDNF)

Author(s): Vinicius S.P. Pedroso*, Érica L.M. Vieira, Aline S. de Miranda, Venugopal R. Venna, Louise D. McCullough and Antonio L. Teixeira

Volume 17, Issue 4, 2020

Page: [495 - 501] Pages: 7

DOI: 10.2174/1567202617999200819155636

Price: $65

Abstract

Background: Stroke is a major cause of death and disability worldwide. Among its complications, post-stroke depression (PSD) leads to a significant burden. The diagnosis of PSD is complex, and there are no biomarkers that can assist in its early identification and adequate management.

Objective: The aim of the present study is to investigate peripheral biomarkers in the acute phase of stroke and their potential association with depressive symptoms.

Methods: We evaluated 60 patients in the acute phase of stroke by using standardized instruments of psychiatric and neurological assessment (Mini International Neuropsychiatric Interview-Plus- MINI-Plus, Hospital Anxiety and Depression Scale-HADS, and National Institutes of Health Stroke Scale-NIHSS) and measured peripheral biomarkers.

Results: In multivariate analysis, low peripheral levels of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) and higher NIHSS scores were associated with PSD. The severity of depressive symptoms was inversely correlated with sTREM-1 and glial cell-derived neurotrophic factor (GDNF) levels.

Conclusion: This is the first study indicating an association between sTREM-1 and PSD. Our results may point to the involvement of glial mechanisms in the manifestation of depressive symptoms after stroke.

Keywords: Stroke, post-stroke depression, biomarkers, sTREM-1, GDNF, cognitive dysfunction.

« Previous Next »
[1]
Virani SS, Alonso A, Benjamin EJ, et al. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation 2020; 141(9): e139-596.
[http://dx.doi.org/10.1161/CIR.0000000000000757] [PMID: 31992061]
[2]
Ayerbe L, Ayis S, Wolfe CD, Rudd AG. Natural history, predictors and outcomes of depression after stroke: Systematic review and meta-analysis. Br J Psychiatry 2013; 202(1): 14-21.
[http://dx.doi.org/10.1192/bjp.bp.111.107664] [PMID: 23284148]
[3]
Ayerbe L, Ayis S, Crichton S, Wolfe CD, Rudd AG. The natural history of depression up to 15 years after stroke: The South London Stroke Register. Stroke 2013; 44(4): 1105-10.
[http://dx.doi.org/10.1161/STROKEAHA.111.679340] [PMID: 23404719]
[4]
Pietra Pedroso VS, Rachid MA, Teixeira AL. Biomarkers in post-stroke depression. Curr Neurovasc Res 2016; 13(2): 163-73.
[http://dx.doi.org/10.2174/1567202613666160219120114] [PMID: 26891661]
[5]
Amorim P. Mini International Neuropsychiatric Interview (MINI): Validation of a short structured diagnostic psychiatric interview. Rev Bras Psiquiatr 2000; 22(3): 106-15.
[http://dx.doi.org/10.1590/S1516-44462000000300003]
[6]
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67(6): 361-70.
[http://dx.doi.org/10.1111/j.1600-0447.1983.tb09716.x] [PMID: 6880820]
[7]
Pedroso VSP, Brunoni AR, Vieira ÉLM, Jorge RE, Lauterbach EC, Teixeira AL. Early psychiatric morbidity in a Brazilian sample of acute ischemic stroke patients. Clinics (São Paulo) 2018; 73: e55.
[http://dx.doi.org/10.6061/clinics/2018/e055] [PMID: 29723343]
[8]
Pedroso VSP, Vieira ELM, Brunoni AR, Lauterbach EC, Teixeira AL. Psychopathological evaluation and use of the Hospital Anxiety and Depression Scale in a sample of Brazilian patients with post-stroke depression. Arch Clin Psychiatry 2016; 43(6): 147-50.
[http://dx.doi.org/10.1590/0101-60830000000102]
[9]
Zera KA, Buckwalter MS. The local and peripheral immune responses to stroke: Implications for therapeutic development. Neurotherapeutics 2020; 17(2): 414-35.
[http://dx.doi.org/10.1007/s13311-020-00844-3] [PMID: 32193840]
[10]
Kim JY, Park J, Chang JY, Kim SH, Lee JE. Inflammation after ischemic stroke: The role of leukocytes and glial cells. Exp Neurobiol 2016; 25(5): 241-51.
[http://dx.doi.org/10.5607/en.2016.25.5.241] [PMID: 27790058]
[11]
Hackett ML, Yapa C, Parag V, Anderson CS. Frequency of depression after stroke: A systematic review of observational studies. Stroke 2005; 36(6): 1330-40.
[http://dx.doi.org/10.1161/01.STR.0000165928.19135.35] [PMID: 15879342]
[12]
Pedroso VSP, Souza LC, Brunoni AR, Teixeira AL. Post stroke depression: Clinics, etiopathogenesis and therapeutics. Arch Clin Psychiatry (São Paulo) 2015; 42(1): 18-24.
[http://dx.doi.org/10.1590/0101-60830000000041]
[13]
Cao C, Gu J, Zhang J. Soluble triggering receptor expressed on myeloid cell-1 (sTREM-1): A potential biomarker for the diagnosis of infectious diseases. Front Med 2017; 11(2): 169-77.
[http://dx.doi.org/10.1007/s11684-017-0505-z] [PMID: 28425045]
[14]
Ravetti CG, Moura AD, Vieira EL, Pedroso ER, Teixeira AL. sTREM-1 predicts intensive care unit and 28-day mortality in cancer patients with severe sepsis and septic shock. J Crit Care 2015; 30(2): 440.e7-440.e13.
[http://dx.doi.org/10.1016/j.jcrc.2014.12.002] [PMID: 25541104]
[15]
Weigelt K, Carvalho LA, Drexhage RC, et al. TREM-1 and DAP12 expression in monocytes of patients with severe psychiatric disorders. EGR3, ATF3 and PU.1 as important transcription factors. Brain Behav Immun 2011; 25(6): 1162-9.
[http://dx.doi.org/10.1016/j.bbi.2011.03.006] [PMID: 21421043]
[16]
Xu P, Zhang X, Liu Q, et al. Microglial TREM-1 receptor mediates neuroinflammatory injury via interaction with SYK in experimental ischemic stroke. Cell Death Dis 2019; 10(8): 555.
[http://dx.doi.org/10.1038/s41419-019-1777-9] [PMID: 31324751]
[17]
Sharma AN, da Costa e Silva BF, Soares JC, Carvalho AF, Quevedo J. Role of trophic factors GDNF, IGF-1 and VEGF in major depressive disorder: A comprehensive review of human studies. J Affect Disord 2016; 197: 9-20.
[http://dx.doi.org/10.1016/j.jad.2016.02.067] [PMID: 26956384]
[18]
Uzdensky A, Komandirov M, Fedorenko G, Lobanov A. Protection effect of GDNF and neurturin on photosensitized crayfish neurons and glial cells J MolNeurosci 2013; 49: 480-90.
[19]
Duarte Azevedo M, Sander S, Tenenbaum L. GDNF, A neuron-derived factor upregulated in glial cells during disease. J Clin Med 2020; 9(2): 456.
[http://dx.doi.org/10.3390/jcm9020456] [PMID: 32046031]
[20]
Ford JW, McVicar DW. TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol 2009; 21(1): 38-46.
[http://dx.doi.org/10.1016/j.coi.2009.01.009] [PMID: 19230638]
[21]
Smith RS. A comprehensive macrophage-T-lymphocyte theory of schizophrenia. Med Hypotheses 1992; 39(3): 248-57.
[http://dx.doi.org/10.1016/0306-9877(92)90117-U] [PMID: 1361959]
[22]
Smith RS, Maes M. The macrophage-T-lymphocyte theory of schizophrenia: Additional evidence. Med Hypotheses 1995; 45(2): 135-41.
[http://dx.doi.org/10.1016/0306-9877(95)90062-4] [PMID: 8531836]
[23]
Beumer W, Gibney SM, Drexhage RC, et al. The immune theory of psychiatric diseases: A key role for activated microglia and circulating monocytes. J Leukoc Biol 2012; 92(5): 959-75.
[http://dx.doi.org/10.1189/jlb.0212100] [PMID: 22875882]
[24]
Barbosa IG, Rocha NP, Assis F, et al. Monocyte and lymphocyte activation in bipolar disorder: A new piece in the puzzle of immune dysfunction in mood disorders. Int J Neuropsychopharmacol 2014; 18(1): pyu021.
[http://dx.doi.org/10.1093/ijnp/pyu021] [PMID: 25539506]
[25]
Maragakis NJ, Rothstein JD. Mechanisms of disease: Astrocytes in neurodegenerative disease. Nat Clin Pract Neurol 2006; 2(12): 679-89.
[http://dx.doi.org/10.1038/ncpneuro0355] [PMID: 17117171]
[26]
Ménard C, Hodes GE, Russo SJ. Pathogenesis of depression: Insights from human and rodent studies. Neuroscience 2016; 321: 138-62.
[http://dx.doi.org/10.1016/j.neuroscience.2015.05.053] [PMID: 26037806]
[27]
Tsybko AS, Ilchibaeva TV, Popova NK. Role of glial cell line-derived neurotrophic factor in the pathogenesis and treatment of mood disorders. Rev Neurosci 2017; 28(3): 219-33.
[http://dx.doi.org/10.1515/revneuro-2016-0063] [PMID: 28099138]
[28]
Naumenko VS, Kondaurova EM, Bazovkina DV, et al. Effect of GDNF on depressive-like behavior, spatial learning and key genes of the brain dopamine system in genetically predisposed to behavioral disorders mouse strains. Behav Brain Res 2014; 274: 1-9.
[http://dx.doi.org/10.1016/j.bbr.2014.07.045] [PMID: 25101543]
[29]
Paumier KL, Sortwell CE, Madhavan L, Terpstra B, Daley BF, Collier TJ. Tricyclic antidepressant treatment evokes regional changes in neurotrophic factors over time within the intact and degenerating nigrostriatal system. Exp Neurol 2015; 266: 11-21.
[http://dx.doi.org/10.1016/j.expneurol.2015.02.005] [PMID: 25681575]
[30]
Ma XC, Chen C, Zhu F, Jia W, Gao CG. Association of the GDNF gene with depression and heroin dependence, but not schizophrenia, in a Chinese population. Psychiatry Res 2013; 210(3): 1296-8.
[http://dx.doi.org/10.1016/j.psychres.2013.08.025] [PMID: 24022000]
[31]
Rajkowska G, Stockmeier CA. Astrocyte pathology in major depressive disorder: Insights from human postmortem brain tissue. Curr Drug Targets 2013; 14(11): 1225-36.
[http://dx.doi.org/10.2174/13894501113149990156] [PMID: 23469922]

Rights & Permissions Print Cite
Article Metrics
39
© 2024 Bentham Science Publishers | Privacy Policy